Glioblastomas are unrelenting. About half of those diagnosed with this highly malignant form of brain cancer die within two years of diagnosis.

Virginia Tech Carilion Research Institute Tackles Hard Problems

Priorclave partner Virginia Tech is pursuing new therapies to treat people with gliobastomas at its Carilion Research Institute. Michael J. Friedlander, founding executive director of the institute and vice president for health sciences and technology at Virginia Tech, said that although other forms of cancer are more common, their scientists chose to work on glioblastomas because there was a lack of effective therapies to deal with this aggressive cancer.

An interdisciplinary research team—bringing together engineering, neuroscience, and biomedical science—are working on several different therapies, including a pioneering personalized cancer medicine that uses a patient’s own cancer stem cells to target the glioblastoma.

The news that Senator John McCain was diagnosed with a glioblastoma has brought public attention to this malignant affliction — and hopefully renewed energy to find solutions that improve quality of life. Priorclave is committed to supporting this work.

“This is a perfect example of why I joined Priorclave,” notes Priorclave North America President and CEO Barbra Wells. “Helping researchers take their budget further and get more done each day. Our autoclaves are ideal for media sterilization in research labs and available in whatever configuration best serves your work.

[Photo credit: Nephron, CC BY-SA 3.0]

SaveSave